//find last space within length $last_space = strrpos(substr($input, 0, $length), ' '); $trimmed_text = substr($input, 0, $last_space);

The Value of Treatment 2016


The Value of Treatment 2016

“Value of Treatment: Bridging the Early Diagnosis and Treatment Gap for Brain Disorders”

On 27th January 2016, EBC’s Value of Treatment project kicked off with a meeting and the release of the first EBC Discussion Paper “Exploring the potential for a holistic care model for brain disorders to close the treatment gap in Europe: development of a workable care model and case studies analysis” , and a comprehensive research framework has been developed for the case studies analysis.

The Value of Treatment research project draws from the EBC Report “The Economic Cost of Brain Disorders in Europe” published in 2005 (Balak and Elmaci 2007) and updated in 2010 (Gustavsson et al. 2011) that provided a solid estimation on the economic costs of brain disorders in Europe. The indirect costs of brain disorders make up for 40 percent of the total costs – which EBC estimated at around 800 billion euros per year in Europe.

In June 2017, the quantitative research phase 2 of the project with case studies analysis will be completed and released. The case study analyses aim to value the socioeconomic impact and health gains of best practice in specific healthcare interventions (clinical practice) in comparison with the cost burden of current care/non-treatment by carrying out combined economic evaluation of specific care pathway services and patient journey/care modelling.

The Value of Treatment Research Project will ultimately provide evidence-based and cost-effective policy recommendations for the adoption and implementation of a more patient-centred and sustainable coordinated care model for brain disorders.






The Value of Treatment (VoT) project is supported through financial contributions from:

Biogen, BMS-Pfizer Alliance, Boehringer Ingelheim GmbH, Grunenthal, Janssen, Livanova, Lundbeck, Medtronic, MSD, Novartis, Pfizer, Roche, Takeda, TEVA Pharmaceuticals, UCB Biopharma, Vifor Pharma, EARLS and EURLSSG.